Quebec Lung Cancer Screening PLUS Trial (QLC+)
COPD, Coronary Artery Calcification
About this trial
This is an interventional other trial for COPD focused on measuring COPD, Coronary Artery Calcification, Lung cancer screening, Undiagnosed disease, Educational intervention, Medication adherence, Untreated disease, Statins, Inhalers
Eligibility Criteria
Inclusion Criteria:
- Patient screened for lung cancer as part of the Quebec Lung Cancer Demonstration project by low dose CT scan of the chest.
- Cardiovascular aim: moderate to severe CAC identified on low dose CT, not on guideline recommended statin therapy.
- COPD aim: diagnosed with COPD, symptomatic (mMRC 2 or greater) and untreated, or not on first line guideline recommended therapy for COPD. (ie. inhaled corticosteroids (ICS) alone or short acting beta agonists alone).
Exclusion Criteria:
- Any participant with a high suspicion of lung cancer, defined as Lung-RADS (Lung Imaging Reporting and Data System) 3 or 4, as this is an inopportune time to initiate new medical therapies.
- Cardiovascular aim: Absent or mild CAC, known clinical atherosclerosis, Diabetes Mellitus.
- COPD aim: asymptomatic, or already on appropriate first line COPD therapy (LAMA, long acting beta agonist (LABA), combined LAMA-LABA, combined LAMA-LABA-ICS).
Sites / Locations
- McGill University Health CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
No Intervention
Other
No Intervention
Other
Control Arm: CVD
Intervention Arm: CVD
Control Arm: COPD
Intervention Arm: COPD
Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. Coronary artery Calcification (CAC) score obtained from lung cancer screening CT Scan images
Patients diagnosed with mild to severe CAC and not on first line guideline recommended therapy. CAC score obtained from lung cancer screening CT Scan images
Patients with untreated COPD or not on first line guideline recommended therapy.
Patients with untreated COPD or not on first line guideline recommended therapy.